Effects of Canagliflozin on Intravascular Volume and Hemodynamics

NCT03190798 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study has been withdrawn from IRB review pending IND revision

Conditions

Type2 Diabetes Mellitus
Cardiovascular Diseases

Interventions

DRUG: Canagliflozin 300mg
DRUG: Placebo

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

[object Object]